{"id":1239,"date":"2026-01-24T08:35:20","date_gmt":"2026-01-24T08:35:20","guid":{"rendered":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/2026\/01\/24\/vandetanib-300-mg-in-metastatic-hereditary-medullary-thyroid-cancer-a-phase-ii-open-label-study\/"},"modified":"2026-01-24T08:35:20","modified_gmt":"2026-01-24T08:35:20","slug":"vandetanib-300-mg-in-metastatic-hereditary-medullary-thyroid-cancer-a-phase-ii-open-label-study","status":"publish","type":"post","link":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/2026\/01\/24\/vandetanib-300-mg-in-metastatic-hereditary-medullary-thyroid-cancer-a-phase-ii-open-label-study\/","title":{"rendered":"VANDETANIB (300 MG) IN METASTATIC HEREDITARY MEDULLARY THYROID CANCER: A PHASE II OPEN-LABEL STUDY"},"content":{"rendered":"
Wells A.S.1<\/sup>, Gosnell J.2<\/sup>, Gagel F.R.3<\/sup>, Moley J.4<\/sup>, Pfister D.5<\/sup>,Sosa J.A.6<\/sup>, Skinner M.A.7<\/sup>, Krebs A.D.8<\/sup>, Vasselli J.9<\/sup>, Schlumberger M.10<\/sup><\/div>\n
1<\/sup>Washington University School of Medicine, St Louis, MO, USA, 2<\/sup>University of California at San Francisco, San Francisco, CA, USA, 3<\/sup>UTMD Anderson Cancer Center, Houston, TX, USA, 4<\/sup>Washington University School of Medicine, St Louis, MO, USA, 5<\/sup>Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 6<\/sup>Yale University School of Medicine, New Haven, CT, USA, 7<\/sup>Childrens Medical Center, Dallas, TX, USA, 8<\/sup>AstraZeneca, Wilmington, DE, USA, 9<\/sup>AstraZeneca, Wilmington, DE, USA, 10<\/sup>Institut Gustave Roussy, Villejuif, France<\/div>\n
\n

Abstract<\/h2>\n

Objectives:<\/strong> Vandetanib (ZACTIMA™) is a once-daily oral agent that selectively targets RET, VEGFR and EGFR signalling pathways. This study evaluated the clinical activity of vandetanib 300 mg in patients with metastatic hereditary medullary thyroid cancer (MTC; study code 6474IL0008).
Methods:<\/strong> Eligible patients had a RET germline mutation or confirmed family history of hereditary MTC, and had measurable disease that was locally advanced and\/or metastatic. Patients received vandetanib 300 mg\/day until disease progression or any other withdrawal criterion was met. The primary assessment was objective tumour response (RECIST every 3 months). Partial or complete responses had to be confirmed with a follow-up scan no less than 4 weeks after the first scan demonstrating the response. Secondary assessments included disease control rate, biochemical response (determined by decrements in plasma levels of calcitonin, a tumour marker for MTC) and safety and tolerability.
Results:<\/strong> Thirty patients (21 female\/9 male; median age 50 years) received initial treatment with vandetanib 300 mg. As of 23 February 2007, the median duration of treatment was 248 days and 18 patients continued to receive vandetanib. Objective tumour assessments demonstrated a confirmed partial response in 17% (5\/30) of patients and stable disease ≥24 weeks in a further 73% (22\/30); the disease control rate was therefore 90% (27\/30). Plasma levels of calcitonin showed sustained reductions from baseline in the majority of patients. Adverse events were manageable and generally consistent with previous vandetanib monotherapy studies. Most adverse events were grade 1 or 2; common adverse events were diarrhoea (63%), nausea (57%), rash (57%) and fatigue (53%).
Conclusions:<\/strong> Vandetanib 300 mg has demonstrated encouraging antitumour activity in patients with metastatic hereditary MTC. A final analysis will be performed in April 2008.<\/div>\n","protected":false},"excerpt":{"rendered":"

Wells A.S.1, Gosnell J.2, Gagel F.R.3, Moley J.4, Pfister D.5,Sosa J.A.6, Skinner M.A.7, Krebs A.D.8, Vasselli J.9, Schlumberger M.10 1Washington University School of Medicine, St Louis, MO, USA, 2University of California at San Francisco, San Francisco, CA, USA, 3UTMD Anderson Cancer Center, Houston, TX, USA, 4Washington University School of Medicine, St Louis, MO, USA, 5Memorial Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45,2,9],"tags":[],"class_list":["post-1239","post","type-post","status-publish","format-standard","hentry","category-volume-7-issue-3","category-journal-articles","category-volume-7"],"_links":{"self":[{"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/posts\/1239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/comments?post=1239"}],"version-history":[{"count":0,"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/posts\/1239\/revisions"}],"wp:attachment":[{"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/media?parent=1239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/categories?post=1239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/tags?post=1239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}